Advances in diagnosis and management of irritable bowel syndrome
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250042Keywords:
IBS, Updates, Diagnosis, ManagementAbstract
Irritable bowel syndrome (IBS) is a common disorder of the digestive tract manifested by chronic abdominal pain and irregular bowel habits. It has significant negative impacts on quality of life and healthcare resources worldwide. IBS is linked to disrupted signaling between the brain and gut, affecting motility, sensation, and microbiota. Diagnosis is almost always clinical using Rome IV criteria and investigations to exclude organic diseases. IBS is subdivided according to stool patterns, with IBS with diarrhea being most common. Management aims to improve symptoms and quality of life. It includes patient education and reassurance, dietary and lifestyle modifications, pharmacotherapy, and psychological approaches. Dietary interventions involve low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet and use of probiotics. Medications such as rifaximin and linaclotide are prescribed for patients with specific IBS types. Cognitive behavioral therapy (CBT) has proven effective in targeting psychological factors contributing to the condition. This narrative review discusses recent advances in the diagnosis and treatment of IBS. It points to the importance of using a multidisciplinary approach in IBS management to address the underlying complexity of this condition. Further research should be conducted to refine diagnostic and therapeutic strategies of IBS to improve its prognosis.
Metrics
References
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17. DOI: https://doi.org/10.1016/S2468-1253(20)30217-X
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. DOI: https://doi.org/10.1053/j.gastro.2009.01.015
Hellstrom PM, Benno P. The Rome IV: Irritable bowel syndrome-A functional disorder. Best Pract Res Clin Gastroenterol. 2019;40-41:101634. DOI: https://doi.org/10.1016/j.bpg.2019.101634
Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020;18(2):392-8. DOI: https://doi.org/10.1016/j.cgh.2019.05.037
Yadav YS, Eslick GD, Talley NJ. Irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. Aliment Pharmacol Ther. 2021;54(1):S24-32. DOI: https://doi.org/10.1111/apt.16624
Sood R, Law GR, Ford AC. Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'? Nat Rev Gastroenterol Hepatol. 2014;11(11):683-91. DOI: https://doi.org/10.1038/nrgastro.2014.127
Ludidi S, Mujagic Z, Jonkers D, Keszthelyi D, Hesselink M, Kruimel J, et al. Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2014;26(8):1104-11. DOI: https://doi.org/10.1111/nmo.12365
Gros M, Gros B, Mesonero JE, Latorre E. Neurotransmitter dysfunction in irritable bowel syndrome: Emerging approaches for management. J Clin Med. 2021;10(15):1. DOI: https://doi.org/10.3390/jcm10153429
Simren M, Tornblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2(2):112-22. DOI: https://doi.org/10.1016/S2468-1253(16)30116-9
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. DOI: https://doi.org/10.2147/CLEP.S40245
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58. DOI: https://doi.org/10.1001/jama.2015.0954
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-88. DOI: https://doi.org/10.1016/S0140-6736(20)31548-8
Pearson S, Openshaw P. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6150):1496. DOI: https://doi.org/10.1136/bmj.2.6150.1496-b
Mearin F, Lacy BE, Chang L, William DC, Anthony JL, Magnus S, et al. Bowel disorders. Gastroenterology. 2016;S0016-5085(16)00222-5.
Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262-70. DOI: https://doi.org/10.1053/j.gastro.2013.08.048
Sood R, Camilleri M, Gracie DJ, Matthew JG, Natalie T, Graham RL, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol. 2016;111(10):1446-54. DOI: https://doi.org/10.1038/ajg.2016.308
Palsson OS, Whitehead WE, Van Tilburg MA, Lin C, William C, Michael DC, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 2016;150(6):1481-91. DOI: https://doi.org/10.1053/j.gastro.2016.02.014
Black CJ, Craig O, Gracie DJ, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110-6. DOI: https://doi.org/10.1136/gutjnl-2020-322519
Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev. 2015;16(3):263-9. DOI: https://doi.org/10.1017/S1463423614000383
Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol. 2000;95(11):3176-83. DOI: https://doi.org/10.1111/j.1572-0241.2000.03197.x
Vasant DH, Paine PA, Black CJ, Lesley AH, Hazel AE, Maura C, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. DOI: https://doi.org/10.1136/gutjnl-2021-324598
Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ. 2015;350:h701. DOI: https://doi.org/10.1136/bmj.h701
Vork L, Weerts Z, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. Neurogastroenterol Motil. 2018;30(2). DOI: https://doi.org/10.1111/nmo.13189
Goodoory VC, Houghton LA, Yiannakou Y, Black CJ, Ford AC. Natural history and disease impact of Rome IV vs Rome III irritable bowel syndrome: A longitudinal follow-up study. Clin Gastroenterol Hepatol. 2022;20(3):569-77. DOI: https://doi.org/10.1016/j.cgh.2021.04.043
Ohlsson B. Extraintestinal manifestations in irritable bowel syndrome: A systematic review. Therap Adv Gastroenterol. 2022;15:17562848221114558. DOI: https://doi.org/10.1177/17562848221114558
Aziz I, Simren M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2021;6(2):139-48. DOI: https://doi.org/10.1016/S2468-1253(20)30212-0
Whitehead WE, Palsson OS, Feld AD, Levy RL, VON Korff M, Turner MJ, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther. 2006;24(1):137-46. DOI: https://doi.org/10.1111/j.1365-2036.2006.02956.x
Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut. 2008;57(11):1545-53. DOI: https://doi.org/10.1136/gut.2008.159723
Goldstein RS, Cash BD. Making a confident diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am. 2021;50(3):547-63. DOI: https://doi.org/10.1016/j.gtc.2021.03.004
Linedale EC, Chur-Hansen A, Mikocka-Walus A, Gibson PR, Andrews JM. Uncertain diagnostic language affects further studies, endoscopies, and repeat consultations for patients with functional gastrointestinal disorders. Clin Gastroenterol Hepatol. 2016;14(12):1735-41. DOI: https://doi.org/10.1016/j.cgh.2016.06.030
Camilleri M. Diagnosis and treatment of irritable bowel syndrome: A review. JAMA. 2021;325(9):865-77. DOI: https://doi.org/10.1001/jama.2020.22532
Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol. 2017;112(1):65-76. DOI: https://doi.org/10.1038/ajg.2016.466
Atieh J, Chedid V, Khoshbin K, Kane S, Camilleri M. Development of a score to predict positive colonic histology in chronic diarrhea assessed in open-access colonoscopy. J Clin Gastroenterol. 2021;55(8):694-701. DOI: https://doi.org/10.1097/MCG.0000000000001414
Vijayvargiya P, Gonzalez Izundegui D, Calderon G, Tawfic S, Batbold S, Camilleri M. Fecal bile acid testing in assessing patients with chronic unexplained diarrhea: Implications for healthcare utilization. Am J Gastroenterol. 2020;115(7):1094-102. DOI: https://doi.org/10.14309/ajg.0000000000000637
Camilleri M, Chedid V. Actionable biomarkers: the key to resolving disorders of gastrointestinal function. Gut. 2020;69(10):1730-7. DOI: https://doi.org/10.1136/gutjnl-2019-320325
Turvill J, Turnock D, Holmes H. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterol. 2018;9(4):285-94. DOI: https://doi.org/10.1136/flgastro-2018-100962
Zhou XL, Xu W, Tang XX, Lai-sheng L, Jiang-feng T, Chen-jing Z, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. DOI: https://doi.org/10.1186/1471-230X-14-121
Arasaradnam RP, Brown S, Forbes A, Mark RF, Pali H, Lawrence K, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018;67(8):1380-99. DOI: https://doi.org/10.1136/gutjnl-2017-315909
Leeds JS, Hopper AD, Sidhu R, Alison S, Narges A, Nigel H, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433-8. DOI: https://doi.org/10.1016/j.cgh.2009.09.032
Wu J, Wang C, Lv L. Diagnostic yield of colonoscopy for organic disease in irritable bowel syndrome and its risk factors: A meta-analysis. Neurogastroenterol Motil. 2023;35(2):e14481. DOI: https://doi.org/10.1111/nmo.14481
Spiegel BM, Gralnek IM, Bolus R, Lin C, Gareth SD, Bruce N, et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc. 2005;62(6):892-9. DOI: https://doi.org/10.1016/j.gie.2005.08.016
Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122(2):107-12. DOI: https://doi.org/10.7326/0003-4819-122-2-199501150-00005
Exarchopoulou K, Papageorgiou A, Bacopoulou F, Elli KM, Dimitrios V, George PC, et al. A biofeedback-assisted stress management program for patients with irritable bowel syndrome: A randomised controlled trial. EMBnet J. 2021;26:e980. DOI: https://doi.org/10.14806/ej.26.1.980
Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71(6):1117-26. DOI: https://doi.org/10.1136/gutjnl-2021-325214
Nanayakkara WS, Skidmore PM, O'Brien L, Wilkinson TJ, Gearry RB. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131-42. DOI: https://doi.org/10.2147/CEG.S86798
Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-22. DOI: https://doi.org/10.1038/ajg.2010.480
Johannesson E, Ringstrom G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600-8. DOI: https://doi.org/10.3748/wjg.v21.i2.600
Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. DOI: https://doi.org/10.1136/bmj.a2313
Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):402-10. DOI: https://doi.org/10.5056/jnm.2011.17.4.402
Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54(5):601-7. DOI: https://doi.org/10.1136/gut.2004.047423
Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003;284(1):G130-7. DOI: https://doi.org/10.1152/ajpgi.00266.2002
Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114(1):21-39. DOI: https://doi.org/10.1038/s41395-018-0222-5
Chey WD, Shah ED, DuPont HL. Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review. Therap Adv Gastroenterol. 2020;13:1756284819897531. DOI: https://doi.org/10.1177/1756284819897531
Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26(4):499-509. DOI: https://doi.org/10.1111/nmo.12292
Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365-74. DOI: https://doi.org/10.1038/ajg.2016.542
Mangel AW, Hicks GA. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. Clin Exp Gastroenterol. 2012;5:1-10. DOI: https://doi.org/10.2147/CEG.S23274
Kinsinger SW. Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag. 2017;10:231-7. DOI: https://doi.org/10.2147/PRBM.S120817
Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(7):937-47. DOI: https://doi.org/10.1016/j.cgh.2015.11.020